Franziska Michor

Franziska Michor

Harvard University

H-index: 79

North America-United States

About Franziska Michor

Franziska Michor, With an exceptional h-index of 79 and a recent h-index of 54 (since 2020), a distinguished researcher at Harvard University, specializes in the field of Cancer, Biostatistics, Computational Biology, Evolutionary Biology.

His recent articles reflect a diverse array of research interests and contributions to the field:

Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

Abstract PR08: Intratumoral heterogeneity drives resistance to Antibody Drug Conjugate therapy: Analysis of the NeoSTAR trial of neoadjuvant Sacituzumab govitecan for localized …

Abstract B008: KDM4C histone demethylase connects redox balance to chromatin remodeling via histone H3 tail clipping

Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy

Abstract PS09-02: Event-free Survival by Residual Cancer Burden (RCB) and Intratumor HER2 Heterogeneity after Neoadjuvant T-DM1 and Pertuzumab for Early-stage HER2-positive …

A pan-cancer single-cell analysis of intratumoral copy number diversity and evolution

Use of early dynamics of clinical and laboratory parameters to predict resistance in patients with metastatic urothelial carcinoma receiving post-platinum atezolizumab

Non-genetic determinants driving the evolutional trajectories of drug-tolerant-persisters in KRAS Non-small cell lung cancer

Franziska Michor Information

University

Position

Associate Professor of Biostatistics

Citations(all)

22942

Citations(since 2020)

10511

Cited By

17061

hIndex(all)

79

hIndex(since 2020)

54

i10Index(all)

166

i10Index(since 2020)

139

Email

University Profile Page

Google Scholar

Franziska Michor Skills & Research Interests

Cancer

Biostatistics

Computational Biology

Evolutionary Biology

Top articles of Franziska Michor

Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial

Clinical Cancer Research

2024/2/27

Abstract PR08: Intratumoral heterogeneity drives resistance to Antibody Drug Conjugate therapy: Analysis of the NeoSTAR trial of neoadjuvant Sacituzumab govitecan for localized …

Cancer Research

2024/2/1

Abstract B008: KDM4C histone demethylase connects redox balance to chromatin remodeling via histone H3 tail clipping

Cancer Research

2024/2/1

Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy

Cancer Cell

2024/1/8

Abstract PS09-02: Event-free Survival by Residual Cancer Burden (RCB) and Intratumor HER2 Heterogeneity after Neoadjuvant T-DM1 and Pertuzumab for Early-stage HER2-positive …

Cancer Research

2024/5/2

Nabihah Tayob
Nabihah Tayob

H-Index: 13

Franziska Michor
Franziska Michor

H-Index: 54

A pan-cancer single-cell analysis of intratumoral copy number diversity and evolution

Cancer Research

2024/3/22

Use of early dynamics of clinical and laboratory parameters to predict resistance in patients with metastatic urothelial carcinoma receiving post-platinum atezolizumab

Cancer Research

2024/3/22

Franziska Michor
Franziska Michor

H-Index: 54

Non-genetic determinants driving the evolutional trajectories of drug-tolerant-persisters in KRAS Non-small cell lung cancer

Cancer Research

2024/3/22

Author Correction: Subclonal cooperation drives metastasis by modulating local and systemic immune microenvironments

Nature Cell Biology

2024/3/5

T-REX17 is a transiently expressed non-coding RNA essential for human endoderm formation

Elife

2023/1/31

Christian Much
Christian Much

H-Index: 8

Franziska Michor
Franziska Michor

H-Index: 54

JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States

Cancer research

2023/1/18

Heterogeneity and transcriptional drivers of triple-negative breast cancer

Cell reports

2023/12/26

What approaches are needed to understand human development and disease?

Developmental Cell

2023/12/18

Peripheral blood TCR clonotype diversity as an age-associated marker of breast cancer progression

Proceedings of the National Academy of Sciences

2023/12/5

Abstract B081: Aurora kinase A inhibition overcomes adaptive resistance to KRAS G12C inhibitor by G1-checkpoint induced apoptosis in KRAS non-small cell lung cancer

Molecular Cancer Therapeutics

2023/12/1

Abstract B080: Non-genetic determinants driving sub-clonal resistance to KRAS G12C combination therapies in KRAS mutant non-small cell lung cancer

Molecular Cancer Therapeutics

2023/12/1

Cd70 Deficiency Impairs CD4+ and CD8+ T-Cell Immune Surveillance in Bcl6-Driven Diffuse Large B-Cell Lymphomas

Blood

2023/11/28

Predicting patient outcomes after treatment with immune checkpoint blockade: A review of biomarkers derived from diverse data modalities

2023/11/21

Mathematical Modeling Identifies Optimum Palbociclib-fulvestrant Dose Administration Schedules for the Treatment of Patients with Estrogen Receptor–positive Breast Cancer

Cancer Research Communications

2023/11/16

A paracrine circuit of IL-1β/IL-1R1 between myeloid and tumor cells drives genotype-dependent glioblastoma progression

The Journal of Clinical Investigation

2023/11/15

See List of Professors in Franziska Michor University(Harvard University)